Sony withdraws its mobile phone business from Southeast Asia
Category: #headlines  By Mateen Dalal  Date: 2019-05-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sony withdraws its mobile phone business from Southeast Asia
  • The move comes under the company’s current strategy of redirecting its focus on Japan, Taiwan, Hong Kong, and Europe.
  • The company expects to lower operating expenditure by almost 50% while reducing overall cost by 57% by 2020.

Sony Corporation (Sony), the renowned Japanese multinational conglomerate, has reportedly announced that it would be withdrawing its mobile phone business from Southeast Asia to redirect its focus towards Japan, Taiwan, Hong Kong and Europe.

Reports cite, apart from Southeast Asia, the list of defocused or non-focused regions, which was unveiled at a recent Sony corporate strategy meeting, also includes Australia and South Korea.

According to a report by MalayMail, the company’s decision to withdraw was fairly predictable as it had stopped releasing any of its new devices in Malaysia and, surprisingly, Indonesia, which as early as 2013 had identified Sony brand mobile phones as the second highest selling devices in the nation.

Sony’s withdrawal from other regions was further highlighted when it halted operations at its manufacturing plant in Beijing in March of 2019. Moreover, the company also expects to lower operating expenditure by almost 50% while reducing overall cost by 57% by 2020.

However, the Japanese technology firm will not be making a complete exit as it would continue to monitor Southeast Asia’s market conditions & business feasibility with a Sony spokesperson stating that the company may consider selling Sony devices directly through Sony stores if a business opportunity arises in the region in future.

The CEO of Sony Corporation, Kenichiro Yoshida recently stated that the firm sees smartphones as an instrument for entertainment and as a component that would be critical in making the Sony hardware brand more sustainable.

Meanwhile, Sony is nurturing a new business idea that leverages its technological prowess to develop products that connects users & creators together. The company is also scheduled to launch its latest smartphone model, Xperia 1 in the upcoming days.

Reportedly, the exact schedule of the withdrawal has not been unveiled yet.

Source Credit:  https://www.marketing-interactive.com/sony-withdraws-mobile-business-from-southeast-asia/

https://www.malaymail.com/news/tech-gadgets/2019/05/26/sony-mobile-exits-from-several-markets-including-south-east-asia/1756445

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Cryptocurrency platform Binance acquires dApp startup DappReview
Cryptocurrency platform Binance acquires dApp startup DappReview
By Mateen Dalal

Binance, a renowned cryptocurrency exchange platform where more than 100 cryptocurrencies are traded, reportedly announced the acquisition of DappReview, an evaluation platform offering advertising and data-driven research services to blockchain-base...

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
By Mateen Dalal

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Ap...

Prescient expands PTX-200 trial after it eradicates cancer completely
Prescient expands PTX-200 trial after it eradicates cancer completely
By Mateen Dalal

Prescient Therapeutics, a renowned small molecule drug development firm aimed at developing new cancer therapies, reportedly announced that it is extending its Phase 1b trial in patients with AML (acute myeloid leukemia) after the disease was complet...